Vyvanse costs?

See the DrugPatentWatch profile for Vyvanse

How Much Does Vyvanse Cost with Insurance?

Vyvanse is an expensive medication. The cost without insurance can range from $750 to $1,500 per month for a 30-day supply, depending on the dosage and strength [1]. This is due to the patent protection held by Shire Pharmaceuticals (now part of Takeda Pharmaceuticals) until at least 2031 [2].

However, using insurance coverage can significantly lower the out-of-pocket costs for Vyvanse patients. According to Express Scripts, a pharmacy benefit manager, the average monthly cost of Vyvanse with private insurance is around $230 [3]. Patients with Medicaid or Medicare may also be able to access Vyvanse at lower costs.

Can Anyone Afford Vyvanse Without Insurance?

For those without insurance, there may be ways to reduce the cost of Vyvanse. Generic or authorized generics are not yet available, but there are some discount programs and resources that may help:

1. Takeda Pharmaceutical Company Limited Patient Assistance Program: This program provides discounted Vyvanse for eligible patients. Patients can register on the Takeda website to start the application process [4].
2. Manufacturer Patient Savings Program: Some pharmaceutical companies offer patient savings programs that can help lower the cost of medications like Vyvanse [5].
3. NeedyMeds: This website connects patients with discounted prescription medications, including Vyvanse [6].
4. Patient Assistance Certificates: Some online platforms can help patients find discounted or free prescriptions, including Vyvanse.

Comparison to Other ADHD Medications

Vyvanse is among the more expensive ADHD medications available. For example, Adderall and Ritalin are generally less expensive [7]. However, these medications may have different side effects and efficacy compared to Vyvanse.

What Happens When Patent Expiration Approaches?

Vyvanse's patent is scheduled to expire in 2031. Once generic versions become available, prices for the medication are expected to decrease. However, it's difficult to predict exactly when generic versions of Vyvanse will launch, as patent disputes and exclusivity extensions can occur [8].

Sources:
[1] - https://www.drugs.com/vyvanse.html
[2] - https://www.drugpatentwatch.com/DrugPatent/Document?id=1457
[3] - Express Scripts. (2022). 2022 Drug Trend Report. Retrieved from https://www.express-scripts.com/pdfs/dtr2022.pdf
[4] - https://www.takedapharmaceutical.com/products/vyvanse/
[5] - Manufacturer Patient Savings Program website (not provided)
[6] - https://www.needymeds.org/
[7] - https://www.drugs.com/
[8] - Drug Patent Watch (Source 2)